We hypothesized that KRAS mutant CRC treated with cetuximab benefit from statin use, because statins may phenoconvert the overactive KRAS protein to a more wildtype KRAS phenotype and thereby render these tumors sensitive to cetuximab treatment. The gene discussed is KRAS; the disease is colorectal carcinoma.